FR2843882B1 - Formulation pharmaceutique de propionate de fluticasone - Google Patents

Formulation pharmaceutique de propionate de fluticasone

Info

Publication number
FR2843882B1
FR2843882B1 FR0309598A FR0309598A FR2843882B1 FR 2843882 B1 FR2843882 B1 FR 2843882B1 FR 0309598 A FR0309598 A FR 0309598A FR 0309598 A FR0309598 A FR 0309598A FR 2843882 B1 FR2843882 B1 FR 2843882B1
Authority
FR
France
Prior art keywords
fluticasone propionate
pharmaceutical formulation
formulation
hydrofluoroalkane
hfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0309598A
Other languages
English (en)
Other versions
FR2843882A1 (fr
Inventor
Alan Leslie Cripps
Paul Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27255761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2843882(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9921396.9A external-priority patent/GB9921396D0/en
Priority claimed from GB0014451A external-priority patent/GB0014451D0/en
Priority claimed from GB0018654A external-priority patent/GB0018654D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FR2843882A1 publication Critical patent/FR2843882A1/fr
Application granted granted Critical
Publication of FR2843882B1 publication Critical patent/FR2843882B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
FR0309598A 1999-09-11 2003-08-04 Formulation pharmaceutique de propionate de fluticasone Expired - Fee Related FR2843882B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9921396.9A GB9921396D0 (en) 1999-09-11 1999-09-11 Pharmaceutical formulation
GB0014451A GB0014451D0 (en) 2000-06-13 2000-06-13 Pharmaceutical formulation
GB0018654A GB0018654D0 (en) 2000-07-28 2000-07-28 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
FR2843882A1 FR2843882A1 (fr) 2004-03-05
FR2843882B1 true FR2843882B1 (fr) 2011-04-22

Family

ID=27255761

Family Applications (4)

Application Number Title Priority Date Filing Date
FR0011547A Expired - Fee Related FR2798290B1 (fr) 1999-09-11 2000-09-11 Formulation pharmaceutique de propionate de fluticasone
FR0202756A Expired - Fee Related FR2820322B1 (fr) 1999-09-11 2002-03-05 Formulation pharmaceutique de propionate de fluticasone
FR0309598A Expired - Fee Related FR2843882B1 (fr) 1999-09-11 2003-08-04 Formulation pharmaceutique de propionate de fluticasone
FR0400541A Expired - Fee Related FR2848453B1 (fr) 1999-09-11 2004-01-21 Formulation pharmaceutique de propionate de fluticasone

Family Applications Before (2)

Application Number Title Priority Date Filing Date
FR0011547A Expired - Fee Related FR2798290B1 (fr) 1999-09-11 2000-09-11 Formulation pharmaceutique de propionate de fluticasone
FR0202756A Expired - Fee Related FR2820322B1 (fr) 1999-09-11 2002-03-05 Formulation pharmaceutique de propionate de fluticasone

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR0400541A Expired - Fee Related FR2848453B1 (fr) 1999-09-11 2004-01-21 Formulation pharmaceutique de propionate de fluticasone

Country Status (12)

Country Link
US (4) US6479035B1 (fr)
EP (1) EP1143930B8 (fr)
JP (1) JP2003509359A (fr)
AT (1) ATE343374T1 (fr)
AU (1) AU7026800A (fr)
CA (1) CA2317999C (fr)
DE (1) DE60031504T2 (fr)
ES (1) ES2274803T3 (fr)
FR (4) FR2798290B1 (fr)
GB (1) GB2354007B (fr)
IT (1) IT1317904B1 (fr)
WO (1) WO2001019342A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814717D0 (en) * 1998-02-23 1998-09-02 Bespak Plc Improvements in drug delivery devices
EP1143930B8 (fr) * 1999-09-11 2008-03-19 Glaxo Group Limited Preparation pharmaceutique renfermant du propionate de fluticasone
AU2206801A (en) * 1999-12-24 2001-07-09 Alan Leslie Cripps Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2469435A1 (fr) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulateurs de lxr
EP1321159A1 (fr) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser
JP2005523905A (ja) * 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
EP1340492A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
EP1957078B1 (fr) * 2005-12-02 2013-08-28 Bayer HealthCare, LLC Dérivés de pyrrolotriazine utiles pour traiter le cancer par inhibition de la kinase aurora
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
CA2940931C (fr) * 2009-10-01 2019-04-30 Adare Pharmaceuticals, Inc. Compositions de corticosteroides administrees par voie orale
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
CN102379846B (zh) * 2011-10-21 2014-07-02 江苏长风药业有限公司 以氢氟烷烃和聚乙二醇为辅料氟替卡松丙酸酯气雾剂制剂
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (fr) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Nanocristaux du propionate de fluticasone
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2015034678A2 (fr) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP3797964B1 (fr) 2019-09-26 2023-06-07 Presspart Manufacturing S.A. Outil de moulage par injection pour inhalateur de dose mesurée
WO2021216779A1 (fr) * 2020-04-21 2021-10-28 Amphastar Pharmaceuticals, Inc. Formulations pharmaceutiques antivirales administrées par l'intermédiaire de dispositifs pour l'administration ciblant les poumons

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629985A (fr) * 1962-11-29
CH634480A5 (de) * 1977-11-25 1983-02-15 Schwarzkopf Gmbh Hans Unter druck stehendes aerosolpraeparat.
DE2949933A1 (de) 1979-12-12 1981-06-19 Wabco Fahrzeugbremsen Gmbh, 3000 Hannover Vorrichtung zum verhindern von schlingerbewegungen eines anhaengers
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB2235627B (en) 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5919827A (en) 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
CA2094266C (fr) 1990-10-18 1999-06-01 Robert K. Schultz Formulations
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
AU663906B2 (en) 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
WO1994013263A1 (fr) 1992-12-09 1994-06-23 Jager Paul D Formulations en aerosol de solutions medicinales stabilisees
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
EE04004B1 (et) 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Flutikasoonpropionaati doseeriv inhalaator
CA2273835A1 (fr) 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Compositions pharmaceutiques et leurs dispositifs d'administration
WO1998034595A1 (fr) * 1997-02-05 1998-08-13 Jago Research Ag Formulations medicales pour aerosols
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
WO1999055600A1 (fr) 1998-04-30 1999-11-04 3M Innovative Properties Company Valve de dosage pour aerosol pharmaceutique
EP1087750B1 (fr) 1998-06-18 2003-11-12 Boehringer Ingelheim Pharmaceuticals Inc. Preparations pharmaceutiques pour aerosols a deux principes actifs ou plus
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
ES2234266T3 (es) 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6231519B1 (en) * 1999-05-04 2001-05-15 Nokia Corporation Method and apparatus for providing air quality analysis based on human reactions and clustering methods
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
EP1143930B8 (fr) * 1999-09-11 2008-03-19 Glaxo Group Limited Preparation pharmaceutique renfermant du propionate de fluticasone
ATE286716T1 (de) 1999-11-23 2005-01-15 Glaxo Group Ltd Pharmazeutische formulierungen enthaltend salmeterol
GB0002798D0 (en) 2000-02-09 2000-03-29 Glaxo Group Ltd Actuator nozzle for metered dose inhaler

Also Published As

Publication number Publication date
ES2274803T3 (es) 2007-06-01
US6630129B2 (en) 2003-10-07
FR2848453A1 (fr) 2004-06-18
US20040037783A1 (en) 2004-02-26
GB2354007B (en) 2003-10-22
FR2798290B1 (fr) 2003-09-12
DE60031504T2 (de) 2007-04-05
EP1143930A2 (fr) 2001-10-17
GB0022222D0 (en) 2000-10-25
FR2820322B1 (fr) 2005-03-11
ATE343374T1 (de) 2006-11-15
FR2798290A1 (fr) 2001-03-16
FR2848453B1 (fr) 2010-09-03
GB2354007A (en) 2001-03-14
WO2001019342A3 (fr) 2001-08-09
DE60031504D1 (de) 2006-12-07
ITRM20000491A1 (it) 2002-03-11
EP1143930B1 (fr) 2006-10-25
AU7026800A (en) 2001-04-17
US20030086876A1 (en) 2003-05-08
EP1143930A3 (fr) 2002-09-11
JP2003509359A (ja) 2003-03-11
US6479035B1 (en) 2002-11-12
ITRM20000491A0 (it) 2000-09-11
FR2843882A1 (fr) 2004-03-05
US7220403B2 (en) 2007-05-22
IT1317904B1 (it) 2003-07-15
CA2317999A1 (fr) 2001-03-11
EP1143930B8 (fr) 2008-03-19
FR2820322A1 (fr) 2002-08-09
CA2317999C (fr) 2004-11-09
WO2001019342A2 (fr) 2001-03-22
US20040157815A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
FR2798290B1 (fr) Formulation pharmaceutique de propionate de fluticasone
AU2206801A (en) Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
DE60308997D1 (de) Formulierungen zur inhalation
PT1037604E (pt) Composicoes farmaceuticas de aerossol
MXPA03000442A (es) Una formulacion medicinal en aerosol.
DK0918507T3 (da) Aerosolformuleringer
HK1042444A1 (zh) 藥用噴霧製劑
GB0016876D0 (en) Novel formulation
EP1523976A3 (fr) Formulations pharmaceutiques de salméterol
CA2446562A1 (fr) Formulation pharmaceutique de propionate de fluticasone
MX9707238A (es) Formulaciones en aerosol de butixocort.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20091130

RN Application for restoration
D3 Ip right revived
ST Notification of lapse

Effective date: 20130531